Body Pharm CJC1295 & Ipamorelin 20 Pen

The Body Pharm CJC-1295 & Ipamorelin 20 Pen is a pre-loaded combination research pen available through JCSG.org for South African researchers. It delivers 20 metered doses of CJC-1295 (no DAC) and Ipamorelin in a fixed blend — no reconstitution required, shipped with validated cold-chain packaging.

Neither CJC-1295 nor Ipamorelin is SAHPRA-registered for human or veterinary use under Act 101 of 1965. This product is sold strictly for in vitro research purposes.

Key Takeaways

• The Body Pharm 20 Pen uses CJC-1295 without DAC (Mod GRF 1-29) paired with Ipamorelin at a fixed ratio — verify the exact ratio against the Certificate of Analysis at delivery.
• Pre-loaded pen format: no bacteriostatic water mixing, lower contamination risk, consistent dose-to-dose delivery across a 20-administration research series.
• Neither CJC-1295 nor Ipamorelin is SAHPRA-registered for human use; supply is lawful only for in vitro research under Act 101 of 1965.
• Cold-chain integrity is the dominant South African logistics risk — JCSG.org ships with validated cool-box packaging and temperature logging.

What Is the Body Pharm CJC-1295 & Ipamorelin 20 Pen?

The Body Pharm CJC-1295 & Ipamorelin 20 Pen is a pre-loaded research device containing a combined CJC-1295 (no DAC) and Ipamorelin blend across 20 metered doses. Body Pharm manufactures it for in vitro research purposes only. Confirm batch-specific mg-per-pen loading, peptide ratio, and storage window against the Certificate of Analysis before use.

CJC-1295 no DAC is the same molecule commonly catalogued as Modified GRF 1-29 (Mod GRF 1-29). It is a 30-amino-acid GHRH (growth hormone-releasing hormone) analogue without the Drug Affinity Complex linker. Conflating no-DAC with the long-acting DAC variant is the most common specification error in purchase orders. For the pharmacokinetic contrast, see the CJC-1295 with DAC page and the broader CJC-1295 research overview.

The pen ships pre-mixed in solution — no reconstitution with bacteriostatic water is required. This product is not registered with SAHPRA for human or veterinary use.

CJC-1295 vs. Ipamorelin: Complementary Mechanisms

CJC-1295 (no DAC) and Ipamorelin stimulate growth hormone release through two distinct receptor pathways, targeting GH pulse amplitude and frequency through separate mechanisms.

CJC-1295 no DAC is a 30-amino-acid GHRH analogue (Mod GRF 1-29) that binds the pituitary GHRH receptor and amplifies the magnitude of endogenous GH pulses. Pre-clinical pharmacokinetic data report a plasma half-life on the order of 20–30 minutes, allowing rapid clearance between pulses.

Ipamorelin is a selective agonist at the growth hormone secretagogue receptor 1a (GHSR-1a) — the same receptor activated by endogenous ghrelin [11]. Activation of GHSR-1a on pituitary somatotrophs triggers an additional GH-release signal that operates independently of the GHRH pathway. That independence is the mechanistic basis for combining both molecules in a single research pen.

The selectivity profile distinguishes Ipamorelin from earlier growth hormone releasing peptides such as GHRP-6. Foundational receptor-binding and endocrine work from the late 1990s and 2000s reported that Ipamorelin produces markedly less stimulation of ACTH (adrenocorticotropic hormone), cortisol, and prolactin than GHRP-6 at comparable GH-releasing doses [12]. The "amplitude plus frequency" rationale for the combination draws from preclinical pharmacology and small-scale human work rather than registered clinical outcome studies and should not be presented as an established therapeutic effect.

For protocol design, see the CJC-1295 with DAC page for the long-acting analogue contrast, and the broader CJC-1295 research overview for the parent compound class.

DAC vs. No-DAC in a Combination Pen: What Changes?

The Body Pharm 20 Pen uses CJC-1295 without DAC. This is the form almost universally paired with Ipamorelin in combination research pens. DAC (Drug Affinity Complex) is a maleimido-lysine modification that binds the peptide to circulating serum albumin, extending the plasma half-life from roughly 30 minutes (no-DAC) to approximately 6–8 days (with DAC). Both half-life figures derive from pre-2020 clinical pharmacokinetic work and should be verified against current literature before being cited in a protocol.

Why combination pens use the no-DAC variant

The pulsatile rationale only holds with the short-acting form. No-DAC CJC-1295 (functionally Mod GRF 1-29) clears within about half an hour, allowing the GHRH-axis signal to rise and fall in a pattern that approximates endogenous secretion. Ipamorelin, acting at GHSR-1a with similarly brief receptor occupancy, amplifies a single pulse on top of that transient GHRH signal. Pairing Ipamorelin with the DAC-modified analogue instead produces a sustained, non-pulsatile GHRH tone that does not replicate physiological pulse architecture.

Practical implications for format choice

The short half-life of no-DAC CJC-1295 means each dose is a discrete event in the research model. Frequency of administration becomes the primary protocol variable rather than steady-state accumulation. Researchers whose protocol specifically requires tonic IGF-1 elevation rather than pulsatile GH release should consult the CJC-1295 with DAC page, or the broader CJC-1295 research overview for variant comparisons. None of the half-life or pulse-mimicry claims above are supported by registered clinical outcome data and should not be read as evidence of therapeutic effect.

Format Options

The Body Pharm CJC-1295 & Ipamorelin 20 Pen sits alongside other research formats. The right choice depends on your protocol's priorities:

Format	Reconstitution?	Ratio Flexibility	Dose Consistency	Best For
Pre-loaded pen (this product)	No	Fixed	High — factory-loaded cartridge	Multi-dose protocols requiring reproducible dosing
Lyophilised blend vial	Yes (BAC water)	Fixed at manufacture	Moderate — dependent on pipetting	Cost-sensitive workflows with in-house reconstitution SOPs
Separate CJC-1295 + Ipamorelin vials	Yes — two vials	Full researcher control	Lower — two-vial workflow	Variable-ratio experimental designs

Pre-Loaded Pen: Advantages for Research

The pre-loaded pen removes reconstitution from the workflow and delivers fixed pre-measured doses across 20 administrations. Practical advantages:

• No bacteriostatic-water mixing step
• Lower contamination risk between doses
• Dose-to-dose consistency that vials cannot match without precise pipetting
• Fewer SOPs and audit points for institutional QA review

The ratio is fixed at the manufacturer's specification — confirm the exact CJC-1295:Ipamorelin ratio against the Certificate of Analysis. For workflows requiring an independently adjustable long-acting GHRH component, the CJC-1295 with DAC variant alongside a separate Ipamorelin vial remains the configurable option.

SAHPRA & South African Regulatory Position (2026)

Under the Medicines and Related Substances Act 101 of 1965, peptides such as CJC-1295 and Ipamorelin are classified as medicines. They cannot be lawfully sold for human consumption in South Africa unless registered and scheduled by SAHPRA. Neither compound holds SAHPRA registration as of 2026, so supply for human use is prohibited. Lawful distribution occurs only under a research-use classification.

"Research purposes only" is not promotional language. It is the legal basis on which an unregistered substance may be supplied to a laboratory, research institution, or qualified investigator for in vitro or non-human experimental work. SAHPRA's communications on unregistered medicines reinforce this principle.

Researchers should verify the regulatory position directly against the SAHPRA website and the Government Gazette before procurement. Retain documentation of research intent, institutional affiliation, and protocol references with every order. The same regulatory framework applies to the CJC-1295 with DAC variant and the formulations covered in our broader CJC-1295 research overview.

Research use only. The Body Pharm CJC-1295 & Ipamorelin 20 Pen is not a registered medicine in South Africa and is not approved by SAHPRA for human or veterinary use. Nothing on this page constitutes medical advice. Human use without a valid prescription from a registered medical practitioner is prohibited under Act 101 of 1965. Verify current SAHPRA guidance before purchase.

Selecting the Right Format

Choose the pre-loaded pen when your protocol requires a fixed ratio, minimal reconstitution handling, and reproducible micro-dosing across a multi-week timeline. Choose a lyophilised blend vial when budget is the primary constraint and your lab has bacteriostatic water, accurate insulin syringes, and documented reconstitution SOPs. Choose separate vials when the protocol calls for variable ratios, independent dose-response curves, or single-peptide control arms.

Decision criteria, in order of weight for most South African research procurement:

• Ratio flexibility required? Yes → separate vials. No (fixed ratio acceptable) → pen or blend vial.
• Reconstitution capability in-house? No or limited → pen. Yes → blend vial or separate vials.
• Dose consistency across a 20+ administration series? Critical → pen. Non-critical → blend vial.
• Price-per-dose the deciding factor? The current ZAR price is shown in the buy box on this page.
• Cold-chain logistics? Pens and vials both require 2–8 °C — JCSG.org ships with validated cool-box packaging.
• Institutional QA review burden? Pens require fewer SOPs and audit points than multi-vial workflows.

The Body Pharm 20 Pen suits multi-dose research protocols where administration consistency and operator convenience are priorities. For projects comparing kinetic profiles, pair the no-DAC pen with the CJC-1295 with DAC variant. Consult the broader CJC-1295 research overview for mechanism context before finalising procurement.

Storage, Handling, and Research Safety Notes

Store the Body Pharm CJC-1295 & Ipamorelin 20 Pen at 2–8 °C. The product-specific in-use window should be confirmed with JCSG.org or from the batch Certificate of Analysis at delivery. A sealed, refrigerated research pen of this class is typically labelled for approximately one year of shelf life at 2–8 °C — verify against Body Pharm's own COA figures.

South African cold-chain integrity is the dominant practical risk. Summer ambient temperatures of 30–40 °C across Gauteng, KwaZulu-Natal, and the Northern Cape can degrade peptide cartridges within hours if a courier handover fails. JCSG.org ships with validated cool-box packaging and temperature logging — inspect for thaw indicators on receipt. Store pens upright in a dedicated 2–8 °C laboratory fridge, not a domestic freezer compartment.

Handling follows standard laboratory practice: nitrile gloves, eye protection, and aseptic technique. These products are sold for in vitro research use only and are not approved by SAHPRA for human or veterinary administration. For DAC-format comparisons within the same protocol, the CJC-1295 with DAC variant follows the same cold-chain principles.

Related Research Peptides

Researchers working with CJC-1295/Ipamorelin frequently scope adjacent peptides into the same protocol design:

• Tesamorelin — a stabilised GHRH(1–44) analogue with a distinct pharmacological profile from CJC-1295. Available as the Body Pharm Tesamorelin 32 Pen for pen-format GHRH-axis research.
• BPC-157 — a pentadecapeptide commonly studied in tissue-recovery models. See the BPC-157 research page for procurement details.
• GHK-Cu — a copper-binding tripeptide in a separate mechanistic category, catalogued on the GHK-Cu page for researchers building complementary peptide panels.
• CJC-1295 with DAC — the long-acting analogue for protocols requiring sustained GHRH tone. See the CJC-1295 with DAC page.
• Full CJC-1295 range — browse all variants on the CJC-1295 research overview.

Frequently Asked Questions